Technical Analysis for ADMP - Adamis Pharmaceuticals Corporation

Grade Last Price % Change Price Change
grade C 1.18 -4.07% -0.05
ADMP closed down 4.07 percent on Friday, August 7, 2020, on 84 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical ADMP trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Earnings Movers Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -4.07%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.07%
Calm After Storm Range Contraction -4.07%
NR7 Range Contraction -4.07%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adamis Pharmaceuticals Corporation, a biopharmaceutical company, engages in the development and commercialization of specialty pharmaceutical products in the therapeutic areas of oncology, immunology and infectious diseases, and allergy and respiratory. The company focuses on the development of small molecule compounds, which comprise APC-100, APC-200, and APC-300 for the treatment of human prostate cancer; telomerase vaccine technologies; and other vaccine technologies for providing protection against various viral infectious agents. Its products under development also comprise TeloB-VAX, a novel cell-based vaccine product for prostate cancer; and Savvy(C31G), a contraceptive gel. The company's allergy and respiratory product pipeline includes Epinephrine Injection USP 1, a pre-filled single dose syringe product for use in the emergency treatment of extreme acute allergic reactions or anaphylactic shock; APC-1000, a steroid hydrofluoroalkane (HFA) metered dose inhaler product for asthma and chronic obstructive pulmonary disease; APC-2000, a generic HFA bronchodilator; and APC-3000, an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis. It has a strategic manufacturing, supply, and product development agreement with Beximco Pharmaceuticals Ltd. The company is based in San Diego, California.
Medicine Health Biopharmaceutical Manufacturing Medical Specialties Infectious Diseases Pharmaceutical Products Prostate Cancer Respiratory Therapy Asthma Dosage Forms Allergy Chronic Obstructive Pulmonary Disease Smoking Cessation Emergency Treatment Inhaler Metered Dose Inhaler Rhinitis

Is ADMP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.51
52 Week Low 0.27
Average Volume 6,026,135
200-Day Moving Average 0.64
50-Day Moving Average 0.76
20-Day Moving Average 1.04
10-Day Moving Average 1.22
Average True Range 0.14
ADX 50.45
+DI 30.43
-DI 10.59
Chandelier Exit (Long, 3 ATRs ) 1.09
Chandelier Exit (Short, 3 ATRs ) 0.91
Upper Bollinger Band 1.51
Lower Bollinger Band 0.56
Percent B (%b) 0.65
BandWidth 91.11
MACD Line 0.16
MACD Signal Line 0.16
MACD Histogram 0.0016
Fundamentals Value
Market Cap 37 Million
Num Shares 31.4 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -1.36
Price-to-Sales 14.86
Price-to-Book 4.42
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.38
Resistance 3 (R3) 1.39 1.33 1.34
Resistance 2 (R2) 1.33 1.28 1.33 1.33
Resistance 1 (R1) 1.26 1.25 1.23 1.25 1.32
Pivot Point 1.20 1.20 1.19 1.20 1.20
Support 1 (S1) 1.13 1.15 1.10 1.12 1.04
Support 2 (S2) 1.07 1.12 1.07 1.03
Support 3 (S3) 1.00 1.07 1.02
Support 4 (S4) 0.99